Amanpreet Brar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Amanpreet Brar has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Aysegul Sari
Izmir Kâtip Celebi University, Türkiye
1 shared publication - Carol Jane Swallow
Department of Surgery, University of Toronto, Toronto, ON M5T 1P5, Canada
1 shared publication - Cherry Pun
Department of Pathology and Laboratory Medicine Sinai Health System Toronto ON Canada
1 shared publication - David Patrick Cyr
Department of Surgical Oncology Princess Margaret Cancer Centre and Mount Sinai Hospital Toronto ON Canada
1 shared publication - Deanna Ng
Department of Surgical Oncology Princess Margaret Cancer Centre and Mount Sinai Hospital Toronto ON Canada
1 shared publication Erin D Kennedy
Department of Surgical Oncology Princess Margaret Cancer Centre and Mount Sinai Hospital Toronto ON Canada
1 shared publication
Latest Publications
- Open Access
- 27 August 2025
- Published by Wiley in Histopathology
- Vol. 88 (2) , 457-470
Multifocal extramural venous invasion is a powerful predictor of adverse oncological outcomes in stages I– III colorectal cancer
Aims: This study aimed to determine the impact of venous invasion (VI) characteristics on oncological outcomes in colorectal cancer (CRC). Methods and Results: Resection specimens from 368 patients with TNM stages I–III CRC were assessed for VI including its presence/absence, location [intramural (IMVI) or extramural (EMVI)], number and size of the largest VI focus. VI and EMVI were identified in 55% and 32% of cases, respectively. EMVI, but not IMVI, was significantly associated with decreased 5‐year recurrence‐free survival (RFS) and disease‐specific survival (DSS) (hazard ratio [HR] 4.2, 95% confidence interval CI [2.6–6.9] and 3.7 [95% CI 1.9–6.9], p < 0.0001, respectively). Multifocal EMVI (mEMVI), defined as 2 or more EMVI foci, was identified in 67% of EMVI‐positive cases. In multivariable analysis, EMVI (HR 2.4 [95% CI 1.3–4.3], P = 0.003) and mEMVI (HR 2.4 [95% CI: 1.3–4.4], P = 0.02) were independently associated with RFS and demonstrated stronger associations than all other examined features, including T and N stage. These associations were maintained when the cohort was expanded to include 113 patients who received neoadjuvant therapy in addition to the original 368 patients who had not (‘expanded cohort’, n = 481). An increasing number of EMVI foci was significantly associated with decreased RFS and DSS ( P < 0.0001). Patients with >5 EMVI foci ( n = 31) had a particularly poor prognosis with 5‐year RFS and DSS of 29% and 56%, respectively. EMVI dimensions were not associated with oncological outcomes. Conclusions: Extramural location and multifocality are features of VI strongly associated with adverse oncological outcomes. If externally validated, incorporation of EMVI multifocality into future reporting protocols merits consideration.
- 27 August 2025
- Published by Wiley in Histopathology
- Vol. 88 (2) , 457-470
Open AccessMultifocal extramural venous invasion is a powerful predictor of adverse oncological outcomes in stages I– III colorectal cancer
Aims: This study aimed to determine the impact of venous invasion (VI) characteristics on oncological outcomes in colorectal cancer (CRC). Methods and Results: Resection specimens from 368 patients with TNM stages I–III CRC were assessed for VI including its presence/absence, location [intramural (IMVI) or extramural (EMVI)], number and size of the largest VI focus. VI and EMVI were identified in 55% and 32% of cases, respectively. EMVI, but not IMVI, was significantly associated with decreased 5‐year recurrence‐free survival (RFS) and disease‐specific survival (DSS) (hazard ratio [HR] 4.2, 95% confidence interval CI [2.6–6.9] and 3.7 [95% CI 1.9–6.9], p < 0.0001, respectively). Multifocal EMVI (mEMVI), defined as 2 or more EMVI foci, was identified in 67% of EMVI‐positive cases. In multivariable analysis, EMVI (HR 2.4 [95% CI 1.3–4.3], P = 0.003) and mEMVI (HR 2.4 [95% CI: 1.3–4.4], P = 0.02) were independently associated with RFS and demonstrated stronger associations than all other examined features, including T and N stage. These associations were maintained when the cohort was expanded to include 113 patients who received neoadjuvant therapy in addition to the original 368 patients who had not (‘expanded cohort’, n = 481). An increasing number of EMVI foci was significantly associated with decreased RFS and DSS ( P < 0.0001). Patients with >5 EMVI foci ( n = 31) had a particularly poor prognosis with 5‐year RFS and DSS of 29% and 56%, respectively. EMVI dimensions were not associated with oncological outcomes. Conclusions: Extramural location and multifocality are features of VI strongly associated with adverse oncological outcomes. If externally validated, incorporation of EMVI multifocality into future reporting protocols merits consideration.